Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.
Fast and robust manufacturing process
Because CeliVax uses B cells and monocytes from a patient’s blood, no additional cell culture process is required, which allows for a fast and efficient manufacturing process.
The manufacturing at GMP facility takes only one day after the collection of the patient’s blood leukocytes, which is both an important merit and great convenience to the doctor and the patient.